ATE342257T1 - Heterozyclische verbindungen und verfahren zur modulierung von cxcr3 funktion - Google Patents

Heterozyclische verbindungen und verfahren zur modulierung von cxcr3 funktion

Info

Publication number
ATE342257T1
ATE342257T1 AT00959489T AT00959489T ATE342257T1 AT E342257 T1 ATE342257 T1 AT E342257T1 AT 00959489 T AT00959489 T AT 00959489T AT 00959489 T AT00959489 T AT 00959489T AT E342257 T1 ATE342257 T1 AT E342257T1
Authority
AT
Austria
Prior art keywords
sub
sup
substituted
unsubstituted
group
Prior art date
Application number
AT00959489T
Other languages
German (de)
English (en)
Inventor
Thomas J Schall
Daniel J Dairaghi
Brian E Mcmaster
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Application granted granted Critical
Publication of ATE342257T1 publication Critical patent/ATE342257T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)
AT00959489T 1999-08-27 2000-08-25 Heterozyclische verbindungen und verfahren zur modulierung von cxcr3 funktion ATE342257T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15121299P 1999-08-27 1999-08-27

Publications (1)

Publication Number Publication Date
ATE342257T1 true ATE342257T1 (de) 2006-11-15

Family

ID=22537783

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00959489T ATE342257T1 (de) 1999-08-27 2000-08-25 Heterozyclische verbindungen und verfahren zur modulierung von cxcr3 funktion

Country Status (8)

Country Link
US (3) US6559160B1 (enExample)
EP (1) EP1216232B1 (enExample)
JP (1) JP4831906B2 (enExample)
AT (1) ATE342257T1 (enExample)
AU (1) AU7080500A (enExample)
DE (1) DE60031285T2 (enExample)
ES (1) ES2272319T3 (enExample)
WO (1) WO2001016114A2 (enExample)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070021493A1 (en) 1999-09-16 2007-01-25 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7671200B2 (en) * 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US8852937B2 (en) 2000-03-30 2014-10-07 Curis, Inc. Small organic molecule regulators of cell proliferation
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
KR100883184B1 (ko) 2000-12-11 2009-02-12 암젠 인코포레이션 Ｃｘｃｒ3 길항제
US6469002B1 (en) * 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
EP1465488A4 (en) * 2001-08-30 2007-04-18 Chemocentryx Inc ARYLAMINES AS INHIBITORS OF THE BINDING OF CHEMOKINE A US28
DE60236605D1 (de) 2001-09-05 2010-07-15 Minerva Biotechnologies Corp Zusammensetzungen und deren verwendung zur behandlung von krebs
US6753428B2 (en) * 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
CA2475879A1 (en) * 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis of quinazolinones
ES2361403T3 (es) * 2002-03-07 2011-06-16 X-Ceptor Therapeutics, Inc. Moduladores de quinazolinona de receptores nucleares.
US7381730B2 (en) * 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
JPWO2003082335A1 (ja) * 2002-04-03 2005-07-28 住友製薬株式会社 新規血糖調節薬及びそのスクリーニング方法
EP1513534A2 (en) * 2002-04-04 2005-03-16 Cv Therapeutics, Inc. Compounds for increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
US20030225288A1 (en) * 2002-04-12 2003-12-04 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
PL211300B1 (pl) * 2002-04-17 2012-05-31 Cytokinetics Inc Związek i kompozycja zawierająca ten związek
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
WO2003094839A2 (en) * 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
EP1513820A4 (en) 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP2402310A1 (en) * 2002-05-24 2012-01-04 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
AU2003236527A1 (en) * 2002-06-14 2003-12-31 Cytokinetics, Inc. Compounds, compositions, and methods
EP1539727B1 (en) * 2002-07-17 2009-02-18 Cytokinetics, Inc. Compounds, compositions, and methods for treating cellular proliferative diseases
EP1537089A4 (en) 2002-07-23 2008-04-16 Cytokinetics Inc CONNECTIONS, COMPOSITIONS AND PROCEDURES
EP1539180A4 (en) * 2002-08-21 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
JP2005539062A (ja) * 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
AU2003277079A1 (en) 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
EP1558585B1 (en) * 2002-10-04 2013-09-25 Prana Biotechnology Limited Neurologically-active compounds
KR20050122220A (ko) * 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 디펩티딜 펩티다제 억제제
WO2004092123A2 (en) * 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
US20050165089A1 (en) * 2003-10-06 2005-07-28 Gustave Bergnes Compounds, compositions and methods
WO2005041888A2 (en) * 2003-11-03 2005-05-12 Cytokinetics, Inc. Pyrimidin-4-one compounds, compositions and methods
JP2007510660A (ja) * 2003-11-07 2007-04-26 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
US7439254B2 (en) 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
JP4452839B2 (ja) * 2004-03-09 2010-04-21 国立大学法人京都大学 Ｃｘｃｒ３阻害剤を含有する医薬組成物
MXPA06011236A (es) 2004-04-02 2007-01-16 Prana Biotechnology Ltd Compuestos neurologicamente activos.
US7375102B2 (en) * 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
US7939538B2 (en) * 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
US20070207996A1 (en) * 2004-08-30 2007-09-06 Auger Kurt R Novel Compositions And Methods Of Treatment
PE20060598A1 (es) 2004-09-13 2006-08-21 Ono Pharmaceutical Co Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5
JP2008514709A (ja) * 2004-10-01 2008-05-08 メルク エンド カムパニー インコーポレーテッド 眼科疾患を治療するための組成物および方法
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
US20110052612A1 (en) 2005-05-31 2011-03-03 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
MX2007016270A (es) 2005-06-27 2008-03-05 Amgen Inc Compuestos aril nitrilo anti-inflamatorios.
EP1940407B1 (en) * 2005-09-26 2010-11-10 Merck Sharp & Dohme Corp. N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamides as androgen receptor modulators
KR20090008217A (ko) 2006-03-10 2009-01-21 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제
KR20150038395A (ko) 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
ES2437997T3 (es) 2006-04-14 2014-01-15 Prana Biotechnology Limited Método de tratamiento de la degeneración macular relacionada con la edad (AMD)
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
AU2007281535A1 (en) * 2006-08-01 2008-02-07 Applied Biosystems, Llc. Detection of analytes and nucleic acids
EP2079739A2 (en) * 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
US8273747B2 (en) 2006-11-02 2012-09-25 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2008085828A2 (en) 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR101653842B1 (ko) 2008-01-04 2016-09-02 인텔리카인, 엘엘씨 특정 화학 물질, 조성물 및 방법
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010045542A2 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
AR084824A1 (es) 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
MX2014000648A (es) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Compuestos heterociclicos y sus usos.
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
WO2014071109A1 (en) 2012-11-01 2014-05-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN113620958A (zh) 2014-03-19 2021-11-09 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
AR099789A1 (es) * 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
PH12018500554B1 (en) 2015-09-14 2024-01-24 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
WO2022014433A1 (ja) * 2020-07-13 2022-01-20 国立大学法人富山大学 Ｎｒ４ａ１拮抗薬を用いた鎮痛薬
US20230321063A1 (en) * 2020-08-20 2023-10-12 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Compositions and methods to reduce neuroinflammation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000516210A (ja) 1996-07-12 2000-12-05 ロイコサイト，インコーポレーテッド ケモカインレセプターアンタゴニストとその使用方法
US5919776A (en) 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US5948775A (en) * 1997-03-19 1999-09-07 American Home Products Corporation 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
AU4830799A (en) * 1998-06-29 2000-01-17 Regents Of The University Of California, The Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
US6617115B1 (en) 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
DE60028227T2 (de) 1999-10-27 2007-03-29 Cytokinetics, Inc., South San Francisco Chinazolinone benutzende verfahren und zusammenstellungen

Also Published As

Publication number Publication date
US20060063763A1 (en) 2006-03-23
JP2003508388A (ja) 2003-03-04
US20030119854A1 (en) 2003-06-26
EP1216232B1 (en) 2006-10-11
DE60031285D1 (de) 2006-11-23
AU7080500A (en) 2001-03-26
EP1216232A1 (en) 2002-06-26
US6559160B1 (en) 2003-05-06
WO2001016114A2 (en) 2001-03-08
ES2272319T3 (es) 2007-05-01
WO2001016114A3 (en) 2001-08-02
US6992084B2 (en) 2006-01-31
JP4831906B2 (ja) 2011-12-07
DE60031285T2 (de) 2007-08-30

Similar Documents

Publication Publication Date Title
ATE342257T1 (de) Heterozyclische verbindungen und verfahren zur modulierung von cxcr3 funktion
ATE164575T1 (de) Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer
ATE205515T1 (de) Versteifte trimethin-cyaninfarbstoffe
DK0652868T3 (da) Hæmmere af c-AMP-phosphodiesterase
DE3781080D1 (de) 2-substituierte-e-kondensierte(1,2,4)triazolo-(1,5-c)pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
NO990227L (no) Heterocykliske forbindelser som farmas°ytika
EP1063228A4 (en) CYCLOALCENE DERIVATIVES, THEIR MANUFACTURING METHOD AND THE USE THEREOF
NZ338016A (en) Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same
KR960703887A (ko) 쿠마린 및 카르보스티릴을 pla₂- 억제제로서 사용하는 방법, 및 쿠마린 및 카르보스티릴, 및 이것들의 제조 방법 및 이것들을 함유하는 약제(use of coumarins and carbostyrils as pla₂-inhibitors. new coumarins and car-bostyrils. process for preparing the same and medica-ments)
WO1998053790A3 (en) Compounds that inhibit the binding of vascular endothelial growth factor to its receptors
EP0398367A3 (en) Dimeric epipodophyllotoxin glucoside derivatives
YU48386B (sh) Katalitički sistem za polimerizaciju alfa-olefina, postupak za izvodjenje polimerizacije i dobijeni polimeri
IL153682A0 (en) Variolin derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
EA199900156A1 (ru) Новые производные эритромицина, способ их получения и их применение в качестве медикаментов
ATE261441T1 (de) Analoga von distamycin-zimtsäurederivaten, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
EA199900528A1 (ru) Новые производные эритромицина, способ их получения и применения в качетве медикаментов
DE60328219D1 (de) Verfahren zur synthese von cycloorganylphosphanen und von di(alkali/erdalkalimetall)oligophosphandiiden
GB2169897A (en) 5- halopyridine-3-carboxamide compounds
RU2002105506A (ru) Способ получения ацелированных 1,3-дикарбонильных соединений
EP0820997A4 (en) PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES
KR840001584A (ko) 세팔로스포린 화합물의 제조방법
Sadek et al. Activated nitriles in heterocyclic synthesis. Synthesis of pyrimidine derivatives.
KR950032236A (ko) (+)2-벤조일-3-(실릴옥시프로피-2(s)-일)아미노 아크릴레이트 유도체 및 그 제조방법
DK350588D0 (da) Kvaterniserede nitrogenholdige forbindelser og fremgangsmaade til fremstilling af samme
AU2002336606A1 (en) Synthesis of 2-cyanoziridine-1-carboxamide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1216232

Country of ref document: EP